middle.news
Imagion Biosystems Advances with FDA IND Filing for HER2 Breast Cancer Imaging Trial
9:28am on Monday 2nd of February, 2026 AEDT
•
Healthcare
Read Story
Imagion Biosystems Advances with FDA IND Filing for HER2 Breast Cancer Imaging Trial
9:28am on Monday 2nd of February, 2026 AEDT
Key Points
IND application lodged with U.S. FDA for MagSense® HER2 Imaging Agent
Phase 2 clinical trial planned to start post-FDA approval in early 2026
Strategic trial partners engaged and study site selection underway
Trial designed in three parts to assess safety, dosing, and diagnostic performance
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Imagion Biosystems (ASX:IBX)
OPEN ARTICLE